survodutide vs retatrutide

survodutide (A-tier) vs retatrutide (S-tier). mechanism, trials, evidence boundaries, dosing literature. side-by-side reference.

survodutide · tier A

Investigational GLP-1/glucagon dual agonist. In a phase 3 obesity trial, mean weight loss was 13.0% versus 5.4% with placebo at 76 weeks. Separate trials studied MASH and liver fibrosis.

a GLP-1 plus glucagon dual agonist with phase 3 obesity data and a breakthrough-tier liver story. still investigational, not FDA-approved.

13.0% mean weight loss at 76 weeks · half-life ~6 days · weight loss

retatrutide · tier S

the most potent weight loss drug ever tested. 24.2% in phase 2, then 28.3% in TRIUMPH-1 phase 3, 30.3% at two years. not approved yet.

the triple agonist with the highest weight-loss number ever recorded in a phase 3 obesity trial. not FDA-approved yet.

28.3% TRIUMPH-1 phase 3 · half-life ~6 days · weight loss

at a glance

• survodutide: tier A · 13.0% mean weight loss at 76 weeks
• retatrutide: tier S · 28.3% TRIUMPH-1 phase 3

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.